The development of primary cutaneous adenoid cystic carcinoma in a patient with ankylosing spondylitis treated with etanercept.
The tumor necrosis factor-alpha (TNF-alpha) inhibitors are widely used in the treatment of some autoimmune disorders with promising results. However, their safety has been questioned with multiple postmarketing reports of increased risk for malignancies. The case of a patient with ankylosing spondylitis who developed cutaneous adenoid cystic carcinoma after three years of treatment with anti-TNF-alpha therapy is discussed.
Cansu
Döndü U
DU
Division of Rheumatology, Department of Internal Medicine, Eskisehir Osmangazi University, Eskiçsehir, Turkey.
Kasifoglu
Timuçin
T
Açkaln
Mustafa
M
Korkmaz
Cengiz
C
D003528:Carcinoma, Adenoid Cystic / Q000139:chemically induced* / Q000473:pathology; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000473:pathology; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept